Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-inhibitor Treated”

21 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 21 results

Early research (Phase 1)Study completedNCT02227940
What this trial is testing

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmALK PositiveMetastatic Pancreatic Adenocarcinoma+2 more
Roswell Park Cancer Institute 38
Testing effectiveness (Phase 2)Study completedNCT03909971
What this trial is testing

Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 109
Large-scale testing (Phase 3)Looking for participantsNCT07300514
What this trial is testing

Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma

Who this might be right for
Maintenance Treatment of Peripheral T-cell Lymphoma
Fudan University 136
Not applicableUnknownNCT06081270
What this trial is testing

Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer

Who this might be right for
Lung Cancer
University of Milano Bicocca 20
Testing effectiveness (Phase 2)Study completedNCT01871805
What this trial is testing

Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 134
Testing effectiveness (Phase 2)UnknownNCT04459078
What this trial is testing

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Adenocarcinoma of the Lung
Hunan Cancer Hospital 63
Testing effectiveness (Phase 2)UnknownNCT05675033
What this trial is testing

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Who this might be right for
Lung AdenocarcinomaStage IV Non-small Cell Lung CancerPD-1 Inhibitor+1 more
Fujian Cancer Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT05456256
What this trial is testing

LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

Who this might be right for
Adenocarcinoma of LungCarcinoma, Non-Small-Cell Lung
Lantern Pharma Inc. 90
Early research (Phase 1)Active Not RecruitingNCT03707938
What this trial is testing

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung CarcinomaALK Gene RearrangementLung Non-Small Cell Carcinoma+4 more
M.D. Anderson Cancer Center 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT03420508
What this trial is testing

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 18
Early research (Phase 1)Study completedNCT01531361
What this trial is testing

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Who this might be right for
Advanced Malignant NeoplasmBRAF Gene MutationMetastatic Malignant Neoplasm+2 more
M.D. Anderson Cancer Center 46
Large-scale testing (Phase 3)Looking for participantsNCT06765109
What this trial is testing

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Who this might be right for
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
Nuvalent Inc. 450
Early research (Phase 1)Looking for participantsNCT07140016
What this trial is testing

Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT00939770
What this trial is testing

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Who this might be right for
Recurrent Childhood Anaplastic Large Cell LymphomaRecurrent Malignant Solid NeoplasmRecurrent Neuroblastoma+3 more
Children's Oncology Group 122
Not applicableEnrolling By InvitationNCT06846736
What this trial is testing

ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study

Who this might be right for
Alk-positive Non-Small Cell Lung CancerALK-inhibitor Treated
Sheba Medical Center 200
Testing effectiveness (Phase 2)Study completedNCT04677595
What this trial is testing

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals 36
Large-scale testing (Phase 3)Not Yet RecruitingNCT06254599
What this trial is testing

SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD 255
Testing effectiveness (Phase 2)Active Not RecruitingNCT04127110
What this trial is testing

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC 68
Not applicableStudy completedNCT04647110
What this trial is testing

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Who this might be right for
ALK-positive NSCLC
Pfizer 549
Post-approval studies (Phase 4)Study completedNCT04541706
What this trial is testing

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Pfizer 100
Next Page